- Neptune Technologies & Bioressources Inc. enters into an exclusive
distribution agreement with AZPA International Inc. for Australia and
New Zealand -
LAVAL, QC, Dec. 19 /CNW Telbec/ - Neptune Technologies & Bioressources
Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) is pleased to announce that it has
entered into an exclusive distribution agreement with AZPA International Inc.
("AZPA International") for Australia and New Zealand. AZPA International, a
leading supplier to the pharmaceutical, nutritional health and cosmetics
industries, has also acquired non-exclusive rights to commercialize Neptune's
products in Southeast Asia and Hong Kong.
The nationwide product launch of Neptune Krill Oil (NKO(R)) in Australia
and New Zealand, claiming cardiovascular and joint health benefits, is
scheduled for February 2008. A pre-requisite for commercializing NKO(R) in
Australia hence New Zealand is obtaining approval as a complementary medicine
from the Therapeutic Goods Administration (TGA) which notification Neptune has
AZPA International joined forces for the commercialization and
distribution of NKO(R) with PharmaLink Pte. Ltd. ("PharmaLink"), a leading
provider of complementary and over-the-counter medicines and a leader in
healthcare sales and marketing in the Asia-Pacific region. PharmaLink will be
reaching the market through its primary care team, its pharmacy/ OTC team and
its specialist/ allied health team.
"It is estimated that 74% of the Australian population has used
complementary medicine in the previous twelve months and usage rates are
expected to rise,(1)" said Thierry Houillon, Vice President of Nutraceuticals
of Neptune. "An estimated annual increase of 18% has been reported for the
complementary medicine market in Australia.(2) We are looking forward to
working with AZPA International and PharmaLink benefiting from this trend and
making NKO(R) a household name in Australia and New Zealand," he added.
PharmaLink, in collaboration with AZPA International, will also prepare a
comprehensive marketing campaign, including medical conventions, tradeshows,
and extensive press and mass media coverage. Selected consumers will be taking
NKO(R) for a period of three months and will subsequently be reporting on
radio & TV talk shows about their experience with NKO(R).
In addition, AZPA International will be working with Lipa
Pharmaceuticals, Australia's leading contract manufacturer to the nutritional
and pharmaceutical industries, which makes products in key growth areas of
complementary and alternative medicines, over-the-counter (OTC) and
1. Source: Cardinal Health. Vitamin, Mineral, Herbal and Nutritional
Supplements, 4 October 2005
2. Source: Complementary Healthcare Council communication, 13 September
About Neptune Technologies & Bioressources Inc.
Neptune develops proprietary health ingredients from underexploited
marine biomasses, such as krill, with its patented extraction process (Neptune
OceanExtract(TM)). Using its proprietary process, the Company is strategically
positioning itself in the health and wellness market.
Natural biomass extraction is now playing an important role in developing
nutrigenomics, the next wave in nutritional research. Through strategic
alliances and partnerships, as well as through clinical studies, the Company
continues to demonstrate the beneficial effects of these products. The Company
develops and markets new formulas and new products for specific applications
in high growth markets such as the nutraceutical, cosmeceutical,
biopharmaceutical and nutrigenomics markets.
Neptune continues to strongly support its strategic development plan to
form partnerships/strategic alliances with worldwide leaders in the
nutraceutical and pharmaceutical industries. Neptune has recently signed
agreements with Nestlé and Yoplait, worldwide leading food manufacturers,
paving its entrance into the global functional food market. According to its
business strategy, negotiations with pharmaceutical companies with the
objective of entering the pharmaceutical market by licensing rights are
NASDAQ and TSX venture exchange does not accept responsibility for the
adequacy or accuracy of this press release.
Statements in this press release that are not statements of historical or
current fact constitute "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks, uncertainties, and other unknown
factors that could cause the actual results of the Company to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are urged to
consider statements labeled with the terms "believes," "belief," "expects,"
"intends," "anticipates," "will," or "plans" to be uncertain and
forward-looking. The forward-looking statements contained herein are also
subject generally to other risks and uncertainties that are described from
time to time in the Company's reports filed with the Securities and Exchange
For further information:
For further information: Toni Rinow, Ph.D., MBA, Corporate Development &
Investor Relations, Neptune Technologies & Bioressources Inc., (450) 687-2262,
firstname.lastname@example.org, www.neptunebiotech.com; Source: Neptune
Technologies & Bioressources Inc.